The latest at Valencell : Milestones in clinical validation studies and a rebranding initiative
We have great news to share from the Valencell team. Today the company announced its licensable fitness sensor technology has reached key milestones, achieving unprecedented validation by an independent study recently presented at this year’s American College of Sports Medicine (ACSM) annual conference and validation testing supported by a National Institute of Health (NIH) Phase II Small Business Innovation Research (SBIR) program.
The ACSM study confirmed Valencell earbud sensors were a valid and reliable instrument for continuous measurement of heart rate during exercise. Additionally, with ongoing research supported by an NIH Phase II SBIR program, Valencell has demonstrated that its technology can accurately assess an individual’s resting metabolic rate (RMR), which can account for approximately 60 percent of one’s daily energy expenditure.
Building on strong industry validation and ongoing research, Valencell is rebranding its sensor technology as PerformTekTM (previously it was referred to as V-LINC™) to better reflect the combination of cutting edge sensors and biometric firmware technology and its role in optimizing athletic performance training and coaching.
For more information, see today’s full release here.